Cord Blood Protein in Anemia Transfusion Study
Part of Blood & lymphatic, Brain & nervous system, Genetic & congenital, Heart & circulation, Immune system & allergy, Women’s health & pregnancy clinical trials.
This study measures a protein (S100B) in cord blood from babies who had or did not need a blood transfusion in the womb for hemolytic disease. It looks for possible markers of brain health.
Summary written for real people, not researchers, by Clin2.
Who can take part
- The mother is pregnant with one baby.
- Hemolytic disease of the fetus and newborn (HDFN) is confirmed by antibodies in the mother's blood.
- Complete medical records are available, including fetal brain blood flow ultrasounds.
- Either the baby has severe anemia requiring a blood transfusion in the womb (study group) or mild or no anemia (control group).
- The mother has not regularly taken SSRI antidepressants during pregnancy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study measures a protein called S100B in umbilical cord blood to learn more about brain development in newborns with fetal growth restriction (FGR), a condition where a baby is smaller than expected. Understanding this protein could help doctors identify babies who may need extra support after birth.
This study tracks pregnancies affected by hemolytic disease of the fetus and newborn (HDFN). It collects information to better understand the condition and improve care. You may join if you are pregnant with a history of a prior affected pregnancy and have a current antibody that could harm your baby.
This study looks at how fetal anemia affects the heart's ability to pump blood. It uses an ultrasound test called the myocardial performance index to check heart function in babies with anemia caused by blood type mismatch or parvovirus infection.
This early-phase study tests whether using a baby’s own cord blood stem cells is safe and feasible for newborns with brain injury from lack of oxygen around birth. It may help researchers find new ways to treat hypoxic-ischemic encephalopathy (brain injury due to oxygen deprivation) in addition to standard care like cooling.
This study is looking at a new way to detect bleeding between the mother and baby during pregnancy (called fetomaternal hemorrhage), which can lead to a blood problem in the newborn called hemolytic disease. The goal is to see if this test can help diagnose the condition earlier and hopefully improve care for the baby.
This study looks at a blood test that might help check brain injury in newborns who had a lack of oxygen at birth. The test could give doctors more information to help care for your baby.
Hear when a new Hypoxia-Ischemia, Brain trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.